NorthWest Biotherapeutics Inc (NWBO)

[ae kusterer]

hoffmann6383

Member Level
Monday, May 16, 2022 4:34:46 PM

Re: None

Post#
474311
of 474525
Some great lines from Dr. Musella in his 5-15-22 presentation. He is the President of the Musella Foundation for Brain Tumor Information and Research, Inc. If you don't have time to listen to the entire presentation check out these points:

(some paraphrasing)

Quote:
The recent dcvax-l trial made excellent use of a synthetic control group and was the first major brain tumor trial to do it the right way!

Quote:
Dcvax trial was actually 20 years long. This is for people who live about a year or two, so you are talking about at least 10 generations of patients died waiting to find out if it is good when we kind of knew it was in the beginning and had very little side effects. So if we could have given it back then we could have saved 20 or 30,000 lives.

Quote:
lol, PFS is actually a good finding, but they probably shouldn’t have included this in the slide because it created so much confusion
Quote:
important thing is when they get to OS

Quote:
it is a valid control group

Quote:
Need to get fda approval now so we can start to use it and start combination trials on it

Quote:
We already know using an immune enhancer will make the vaccine work better, using a checkpoint inhibitor will make it work better, probably using optune will make it work better, so many combinations we can try
Quote:
Side effects is like getting the flu shot

pgsd

Member Level
Monday, May 16, 2022 11:48:00 PM

Re: None

Post#
474470
of 474527
Gregory Zivic, MD
@metacollectiveG
$NWBO by the way, DCVax-L trial had only 7 out of 331 patients with IDH-1 mutation (a now known beneficial mutation for survival) In the Optune trial $NVCR had almost 50% IDH-1 mutation. Let’s think hard about these issues please and keep focused. We have approvable data here.

$NWBO by the way, DCVax-L trial had only 7 out of 331 patients with IDH-1 mutation (a now known beneficial mutation for survival) In the Optune trial $NVCR had almost 50% IDH-1 mutation. Let’s think hard about these issues please and keep focused. We have approvable data here. pic.twitter.com/MACvn0Z2BQ

— Gregory Zivic, MD (@metacollectiveG) May 17, 2022

Gregory Zivic, MD
@metacollectiveG

$NWBO Marnix Bosch at 32:32 of the presentation confirms only 7 out of 331 patients in #DCVax P3 trial were IDH-1 mutations. Thus IDH-1 status, which is a large part of most cohorts, did not contribute to the success of the P3 trial. And it WAS successful

$NWBO Marnix Bosch at 32:32 of the presentation confirms only 7 out of 331 patients in #DCVax P3 trial were IDH-1 mutations. Thus IDH-1 status, which is a large part of most cohorts, did not contribute to the success of the P3 trial. And it WAS successfulhttps://t.co/A5RTohZ8cd

— Gregory Zivic, MD (@metacollectiveG) May 17, 2022

Seamlessly connect w/ the markets on the E*TRADE Mobile app
Recent NWBO News
Quarterly Report (10-q) • Edgar (US Regulatory) • 05/10/2022 10:02:07 AM
Amended Annual Report (10-k/a) • Edgar (US Regulatory) • 05/02/2022 09:05:06 PM
TNS Issues New Reports on Stocks with Potential Near Term Catalysts and a Feature Green Energy NASDAQ Report • InvestorsHub NewsWire • 04/12/2022 12:30:00 PM
TNS Feature Report and Next Gen Tech and Biotech That Could Change Our Lives • InvestorsHub NewsWire • 03/17/2022 12:00:00 PM
Seeking Alpha - ALYI sees substantial interest for new EV taxi program • InvestorsHub NewsWire • 03/04/2022 02:11:16 PM
Annual Report (10-k) • Edgar (US Regulatory) • 03/01/2022 05:49:59 PM
Northwest stock rises 9% as company begins cancer vaccine production at UK facility • Seeking Alpha • 02/17/2022 02:49:34 PM
Biopharma Companies Setting up for a Rebound in the Near Term and a New Blockchain Feature Report • InvestorsHub NewsWire • 02/16/2022 01:00:00 PM
SA Breaking News - PURA sees 2022 revenue upside potential to $10M • InvestorsHub NewsWire • 12/15/2021 02:28:27 PM
Northwest Biotherapeutics secures $15M financing on stock purchase rights • Seeking Alpha • 11/29/2021 04:11:27 PM
Quarterly Report (10-q) • Edgar (US Regulatory) • 11/15/2021 09:41:30 PM
IQST Has Catalysts On Deck That Expose A Valuation Disconnect of Roughly 100% - Here's Why That Gap Should Close • InvestorsHub NewsWire • 11/05/2021 02:20:59 PM
iQSTEL, Inc. - The Calm Before The Surge (OTCQX: IQST) • InvestorsHub NewsWire • 10/29/2021 06:31:48 PM
Star Alliance Intl. Corp. (OTC Pink: STAL) Recent Gold Mine Acquisition NI43-101 • InvestorsHub NewsWire • 10/29/2021 11:08:34 AM
IQST - EV & Hi-Tech Company Poised For Potential 4X ROI - Q3 Financials and Short Squeeze • InvestorsHub NewsWire • 10/14/2021 03:34:44 PM
CEO Presenting on the Emerging Growth Conference on October 13 Register Now • InvestorsHub NewsWire • 10/11/2021 11:00:00 AM
CLS Holdings, (OTCQB: CLSH) New Joint Venture $19 million Sales 61% Growth • InvestorsHub NewsWire • 09/28/2021 11:24:31 AM
CEO Presenting on the Emerging Growth Conference on September 29 Register Now • InvestorsHub NewsWire • 09/27/2021 12:35:40 PM
CEO Presenting on the Emerging Growth Conference Tomorrow. Register Now • InvestorsHub NewsWire • 09/14/2021 11:00:00 AM
CEO Presenting on the Emerging Growth Conference on September 15. Register Now • InvestorsHub NewsWire • 09/13/2021 11:00:00 AM
CEO Presenting on the Emerging Growth Conference on September 1. Register Now • InvestorsHub NewsWire • 08/31/2021 11:00:00 AM
CLS Holdings, (OTCQB: CLSH) July Sales $1.9 Million 104% increase over July 2019 • InvestorsHub NewsWire • 08/17/2021 11:21:24 AM
Quarterly Report (10-q) • Edgar (US Regulatory) • 08/16/2021 08:41:47 PM
CEO Presenting on the Emerging Growth Conference on August 4. Register Now • InvestorsHub NewsWire • 08/03/2021 11:00:00 AM
WSGF - World Series of Golf Inc VERY BULLISH Signal Continues • InvestorsHub NewsWire • 08/02/2021 01:45:22 PM
More NWBO News
I